Physician

Bela Faltay, MD

According to 2025 Medicare claims, Bela Faltay, MD (NPI: 1356310247) practices allergy/immunology, with the plurality of this provider's patient population coming from Tuscarawas, OH. This provider's primary affiliated billing organization is THE CLEVELAND CLINIC FOUNDATION (NPI: 1679525919; TIN: 340714585) and primary practice location at 44718-2379. Faltay is affiliated with the Cleveland Clinic Medicare ACO, LLC (ACO ID: A2729), participating under the MSSP model.

Faltay's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 167 traditional Medicare patients, billed 3,475 HCPCS/CPT codes, and received $72,921 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,313 prescription claims across 444 beneficiaries totaling $2,349,027 in drug costs, led by Takhzyro (Lanadelumab-Flyo). 2023 DME data shows 32 claims. Open Payments data shows 1 records totaling $18. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $546,435 to $2,349,027. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,819 to $1,030.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	240	4,894	$64,965
2016	259	2,790	$47,482
2017	262	2,561	$45,978
2018	280	1,391	$38,414
2019	248	415	$23,677
2020	208	337	$15,382
2021	215	1,208	$36,011
2022	195	2,960	$56,935
2023	162	2,274	$53,436
2024	167	3,475	$72,921

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	374	2,287	$546,435
2016	392	2,765	$747,829
2017	412	3,031	$1,250,131
2018	464	3,225	$1,882,737
2019	455	3,022	$2,497,483
2020	413	2,872	$2,485,605
2021	420	2,866	$2,135,195
2022	405	2,633	$2,187,592
2023	433	2,360	$1,853,978
2024	444	2,313	$2,349,027

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	334	$236,290
2016	13	334	$300,431
2017	11	218	$122,689
2018	N/R	140	$103,848
2019	11	83	$46,695
2020	N/R	43	$51,073
2021	N/R	N/R	N/R
2022	N/R	39	$467
2023	N/R	32	$610
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	55	55	$136
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	15	15	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	117	174	$80
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	50	65	$12
95004	Test for allergy using allergenic extract	18	689	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	13	364	$562,304
Xolair	Omalizumab	65	1,820	$270,094
Dupixent Pen	Dupilumab	45	1,232	$169,322
Cuvitru	Immun Glob G(Igg)/Gly/Iga Ov50	15	392	$120,374
Fasenra Pen	Benralizumab	15	728	$85,833

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$18	Pharming Healthcare, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bela Faltay, MD?

Tedicare shows public-source Medicare data for Bela Faltay, MD (NPI 1356310247), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bela Faltay, MD have ACO affiliation data?

Bela Faltay, MD is shown with ACO affiliation data for Cleveland Clinic Medicare ACO, LLC (MSSP, ACO ID A2729).

What billing organization is linked to Bela Faltay, MD?

Bela Faltay, MD is linked to THE CLEVELAND CLINIC FOUNDATION (billing NPI 1679525919) in the available physician profile data.

Does Bela Faltay, MD have Open Payments data?

Bela Faltay, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.